Alpha1-Proteinase Inhibitor for Alpha-1 Antitrypsin Deficiency

(SWIFT-SC Trial)

This trial tests a treatment for individuals with Alpha-1 Antitrypsin Deficiency, a genetic condition that can impair lung function. The study compares two doses of Alpha1-Proteinase Inhibitor, a protein replacement therapy, administered either subcutaneously or intravenously, to evaluate how the body processes them and to ensure their safety. Adults diagnosed with Alpha-1 Antitrypsin Deficiency who experience symptoms like shortness of breath or frequent lung issues may qualify. Participants will be assigned to a treatment group and will know which treatment they receive. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

If you are currently receiving alpha1-PI augmentation therapy, you will need to stop this treatment at the start of the trial and only use the study's treatments. The protocol does not specify about other medications, but it is recommended to maintain a stable dose of systemic steroids if you are taking them.

Research has shown that Alpha1-Proteinase Inhibitor is generally safe and well-tolerated. Studies have demonstrated that weekly doses of both 60 mg/kg and 120 mg/kg are safe for individuals with Alpha-1 Antitrypsin Deficiency. Specifically, one study found that the 120 mg/kg dose did not trigger an immune response and was well-tolerated by participants. Another study indicated that long-term use of the 60 mg/kg dose was also safe, with only a few side effects. Common side effects might include headaches or minor respiratory issues like coughs or colds. Overall, previous research indicates that the treatment has a good safety record.¹²³⁴⁵

Researchers are excited about the investigational Alpha1-Proteinase Inhibitor treatments for Alpha-1 Antitrypsin Deficiency because they offer potentially improved delivery and dosing options compared to current therapies. Unlike standard treatments, which often involve regular intravenous infusions, these new options include subcutaneous administration, allowing for easier self-administration at home. The trial explores two different dosing regimens, which could provide more personalized treatment options based on patient needs. This flexibility not only aims to improve patient convenience and adherence but also could enhance the overall effectiveness of managing this genetic condition.

This trial will evaluate different dosing regimens of Alpha1-Proteinase Inhibitor for Alpha-1 Antitrypsin Deficiency. Research has shown mixed results for this treatment. Some studies suggest it can slow the decline in lung function, as seen in breathing tests. However, other research has not consistently demonstrated clear health benefits. Observational studies suggest that patients on this treatment might live longer, but the overall evidence remains unclear. Despite this, the treatment is generally considered safe and may help maintain stable levels of protective proteins in the blood.⁶⁷⁸⁹¹⁰